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the related article beginning on page XXX). CD133 was thought previously to have a very restricted distribution within tissues; the authors have utilized genetic knock-in models to demonstrate that CD133 in fact is expressed on a wide range of differentiated epithelial cells in adult mouse tissues and on spontaneous primary colon tumors in mice.
In primary human colon tumors all of the epithelial cells also expressed CD133, whereas metastatic colon cancers isolated from liver had distinct CD133 + and CD133 -epithelial populations. Intriguingly, they demonstrate that both the CD133 + and CD133 -populations were equally capable of tumor initiation in xenografts. In light of these new findings, the popular notion that CD133 is a marker of colon CSC may need to be revised.
Until now, there has been little controversy over whether the protein CD133 is a marker of CSC. Originally described as a marker of normal hematopoietic stem cells [1, 2] , it has gained more prominence as a marker of CSCs in solid primary tumors such as meduloblastomas and gliobastomas [12, 13] , and subsequently of CSCs in a growing number of cancers of epithelial tissues. Shmelkov etal challenges this growing dogma;
first, on the basis of CD133's wide distribution in many epithelial tissues, and second, because CD133 expression does not necessarily correlate with colon tumors ability to metastasize ( Figure 1 ).
Normal distribution of CD133 in vivo
CD133 (also known as prominin-1) is a surface protein with five transmembrane domains. Still mysterious in its function, this pentaspan has drawn a lot of attention since its discovery in 1997 on normal human hematopoietic stem cells [1, 2] . The simultaneous discovery of the mouse homologue and its implications in neurogenesis opened up new directions for studying human neural stem cells [3, 4] and several reports have linked CD133 to multiple organ-specific stem cells and referred to it as "the molecule of the moment" [5] .
Prior to the current report by Shmelkov et al. in this issue of the JCI [6] , studies of CD133 as both a normal stem cell marker or a CSC marker have used only one monoclonal antibody against CD133, the clone known as AC133, which marks an epitope of CD133 at the cell surface [1, 2] . Using a single monoclonal antibody to define a stem cell marker is usually not sufficient and it is nnot clear to us why such a practice was so widely accepted. The current study by Shmelkov et al. is, to our knowledge, the first report that uses a knock-in reporter mouse to track expression of CD133 both temporally and spatially, in normal tissues and during tumorigenesis in vivo. In their previous studies, Shmelkov et al.dissected the regulatory region of the human CD133 gene, demonstrating that CD133 expression was regulated in a tissue-specific manner by multiple alternative promoters [7] . Importantly, they identified similarities among the mouse and human regulatory regions, which paved the way for the design of their CD133
reporter mouse. The knock-in mouse described in their latest study possesses the lacZ reporter gene controlled by all endogenous CD133 promoters and thus provides a far more accurate representation of CD133 tissue-specific gene expression compared with AC133 monoclonal antibody staining alone(AUTHOR: in comparison with earlier studies using AC133, specifically? Please complete the comparison)(6).
Using this genetic mouse model, the authors show that CD133 expression is widely distributed in the luminal layer of a number of epithelial tissues throughout the body, a surprising fnding (AUTHOR: Was this observation expected or surprising?) (6) . But could the authors claim that lacZ expression precisely reflects the expression pattern of the endogenous CD133 protein? This approach also has some potential caveats: (i) the lacZ reporter reflects the transcriptional activity of the CD133 gene and not the expression of the CD133 protein; and (ii) considering the high proliferative activity of epithelial tissues, it is possible that due to its half-life, the β-galactosidase activity could still be found in cells after the expression of CD133 was turned off. The authors, however, foresaw these caveats and addressed them with confirmatory CD133
antibody staining in their mice to substantiate the data obtained with the lacZ reporter.
Furthermore, in adult human colon, Shmelkov et al. used the AC133 antibody to demonstrate a pattern of CD133 expression that paralleled their mouse studies. Other recent reports also have shown that CD133 is expressed on mature epithelium of pancreatic ducts in human [8] , in the proximal tubules of the kidney, and the lactiferous ducts of the mammary gland [9] . Based on these findings, one may conclude that CD133 expression in humans likely reflects that in mice, and it is suggested that CD133
demarcates differentiated epithelium in these organs.
Previous reports observed that only a few cells in the colon are CD133 + [10, 11] , whereas Shmelkov et al. (6) demonstrate that all luminal epithelial cells in the colon express CD133 in mice and humans. They contend that the cellular localization of CD133 is on the protrusions of cell membranes [3] . Thus, on the epithelial lining of many organs, CD133 could be positioned on the apical surface, at the border between the plasma membrane and the lumen, perhaps complicating the interpretation of results as it could be mistakenly deemed as an artifact of rim staining. Additionally, it seems that a careful handling of tissues was necessary to preserve the intact brush borders, and it may be essential to examine the different areas of the tissue to make certain that the luminal surface is included in the analysis (Figure 1 The first report that linked CD133 expression to CSCs was published less than five years ago [12, 13] . The CD133 + , but not CD133 -cells in glioma were shown to be tumorigenic in NOD-SCID mice. Since then, many more studies proposed CD133 as a marker of tumor-initiating cells in organs such as prostate [14] , liver [15] , pancreas [16] , the primary tumors microscopically, and did not functionally assess tumor-initiating activity as had been done previously [10, 11] , one could argue that their conclusion that CD133 expression does not segregate with the CSCs in primary colon tumors is not yet fully proven. Nevertheless, upon retrospective assessment of the FACS plots in the two previous colon cancer studies [10, 11] it appears that the entire population of normal and tumor epithelial cells indeed express at least some CD133; perhaps a more appropriate description of the colon CSC would be CD133 hi (not CD133 + ). Thus the important distinction would not be the mere presence of CD133, but the relative abundance of the protein at the cell surface. Even so, more rigorous proof will be required to establish that (such as the kidney capsule, as in ref. [10] ) versus non-privileged sites (such as the subcutaneous space utilized in ref. [11] and in the current study by Shmelkov et al. (6)).
Ultimately, the report from Shmelkov et al. (6) 
